OSAKA -- Japan's Rohto Pharmaceutical said Tuesday it plans to launch clinical trials in August for a stem cell-based treatment for patients suffering severe symptoms induced by the novel coronavirus.
The Osaka-based drugmaker looks to verify the safety and effectiveness of the remedy by December 2021 when the tests will close, then quickly put it on the market.
